A group of advisers from the Food and Drug Administration, the FDA, will decide on November 30 whether to recommend the emergency use of the pill against covid-19 from Merck and Ridgeback Pharmaceuticals.
According to the Merck results, molnupiravir reduces hospitalizations and deaths by 50%.
However, no clinical trials have been conducted in pregnant women and there is concern that it may be dangerous for developing fetuses.